Monoclonal antibody
Type Whole antibody
Source Human
Target kallikrein
Clinical data
ATC code none
CAS Number 1426055-14-2
ChemSpider none
Chemical and physical data
Formula C6468H10016N1728O2012S47
Molar mass 145.7 kDa

Lanadelumab (INN) is a human monoclonal antibody designed for the prevention of angioedema in patients with hereditary angioedema.[1][2]

This drug was developed by Dyax Corp.


  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Lanadelumab, American Medical Association.
  2. World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
This article is issued from Wikipedia - version of the 11/23/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.